Impact of RAAS Inhibitors on Clinical Outcome and Mortality in Patients With STEMI During the COVID-19 Era: A Multicenter Observational Study.
COVID-19
RAAS inhibitors
STEMI patients
mortality
outcome
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
10
2021
accepted:
30
11
2021
entrez:
10
1
2022
pubmed:
11
1
2022
medline:
11
1
2022
Statut:
epublish
Résumé
Conflicting results are available regarding the influence of ACEi/ARBs on the risk of COVID-19 infection, while less is known about their impact on the clinical outcome of patients with STEMI diagnosed with COVID-19. Our aim was to evaluate the impact of ACEi/ARBs therapy on in-hospital mortality and clinical outcomes of patients with STEMI during the COVID-19 pandemic. We retrospectively analyzed consecutive patients with STEMI hospitalized from February 20 to May 10, 2020 in four Hospitals in Lombardy. SARS-COV-2 diagnosis was performed by nasopharyngeal swab test. Procedural outcome, respiratory complications, and in-hospital mortality were reported. Univariate and multivariate analyses were performed by logistic regressions. Our population was represented by 182 patients with STEMI, 76.9% of which were males, and mean age was 67 ± 12.5. Hypertension was reported in 53.3%, and 29.1% was treated with ACEi/ARBs. COVID-19 diagnosis was confirmed in 17.1% of the patients. In-hospital mortality (13.2%) was significantly higher in patients with COVID-19 (31 vs. 10%,
Identifiants
pubmed: 35004902
doi: 10.3389/fcvm.2021.792804
pmc: PMC8739948
doi:
Types de publication
Journal Article
Langues
eng
Pagination
792804Informations de copyright
Copyright © 2021 Barbieri, Trabattoni, Stefanini, Vizzardi, Tumminello, Assanelli, Adamo, Pivato, Provenzale, Gentile, Metra and Carugo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
West J Emerg Med. 2020 Apr 13;21(3):470-472
pubmed: 32302278
N Engl J Med. 2020 Jun 18;382(25):2441-2448
pubmed: 32356628
Circulation. 1998 Jun 9;97(22):2202-12
pubmed: 9631869
Circulation. 2020 Jun 23;141(25):2113-2116
pubmed: 32352306
J Am Coll Cardiol. 2017 Sep 26;70(13):1543-1554
pubmed: 28935030
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
Am J Cardiol. 1997 Oct 1;80(7):859-64
pubmed: 9381998
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
JAMA Cardiol. 2020 Jul 1;5(7):825-830
pubmed: 32324209
Exp Physiol. 2008 May;93(5):631-8
pubmed: 18192334
Biochem Biophys Res Commun. 2020 Feb 17;:
pubmed: 32081428
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Emerg Microbes Infect. 2020 Dec;9(1):757-760
pubmed: 32228222
J Cardiovasc Pharmacol. 1991;18 Suppl 2:S105-9
pubmed: 1725016
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
J Am Coll Cardiol. 1993 Nov 15;22(6):1557-63
pubmed: 8227822
JAMA. 2020 Jul 14;324(2):168-177
pubmed: 32558877
J Am Heart Assoc. 2014 Sep 16;3(5):e001106
pubmed: 25227406
JAMA Cardiol. 2020 Sep 1;5(9):1020-1026
pubmed: 32936273
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
BMJ. 2020 Apr 2;369:m1313
pubmed: 32241880
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
N Engl J Med. 2020 Jun 18;382(25):2431-2440
pubmed: 32356627
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
Circ Cardiovasc Qual Outcomes. 2020 Apr;13(4):e006631
pubmed: 32182131